Orphan designation: rilzabrutinib Treatment of immunoglobulin G4-related disease, 22/08/2025 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 10 April 2026 - 10:39

Orphan designation: rilzabrutinib Treatment of immunoglobulin G4-related disease, 22/08/2025 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3120

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters